NTRK gene-fusions are rare but can occur in diverse cancers. The NTRK
inhibitor larotrectinib is newly approved by the FDA. This paper reports
the first case of a man with a NTRK-rearranged soft tissue sarcoma
treated with larotrectinib in the neoadjuvant setting, in Belgium, to
avoid limb amputation.